Impact Factor 2020: 1.226 (@Clarivate Analytics)
5-Year Impact Factor: 2.285 (@Clarivate Analytics)
Immediacy Index: 2.645
  • Users Online: 1505
  • Print this page
  • Email this page

    Article Cited by others

ORIGINAL ARTICLE

Long-term safety follow-up of children from a randomized—controlled phase II b proof—of—concept efficacy study of the live, attenuated, tetravalent dengue vaccine (CYD—TDV) in Thailand

Limkittikul Kriengsak, Hattasingh Weerawan, Chansinghakul Danaya, Sabchareon Arunee, Dulyachai Wut, Frago Carina, Wartel T Anh, Langevin Edith, Gailhardou Sophia, Bouckenooghe Alain

Year : 2019| Volume: 12| Issue : 9 | Page no: 396-403

   This article has been cited by
 
1 Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9–50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study
Diana Leticia Coronel-MartÍnez,Juliana Park,Eduardo López-Medina,María Rosario Capeding,Andrés Angelo Cadena Bonfanti,María Cecilia Montalbán,Isabel Ramírez,María Liza Antoinette Gonzales,Carlos A DiazGranados,Betzana Zambrano,Gustavo Dayan,Stephen Savarino,Zhenghong Chen,Hao Wang,Sunny Sun,Matthew Bonaparte,Andrey Rojas,Jenny Carolina Ramírez,Mae Ann Verdan,Fernando Noriega
The Lancet Infectious Diseases. 2020;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article